

# Maine Naloxone Distribution Initiative

## Project-To-Date Totals through June 30, 2025


Prepared by the Margaret Chase Smith Policy Center  
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through March 2025, with a particular emphasis on the first quarter of 2025. Additionally, subcategories of naloxone distribution from Tier 1 organizations to the Overdose Prevention Through Intensive Outreach Naloxone and Safety (OPTIONS) initiative and syringe services/access programs in 2021 as well as EMS Naloxone Leave Behind Program are provided.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General's (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Currently, it is hard to measure the effectiveness of naloxone distribution because the total number of overdose reversals relies on voluntary reporting. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.

Monthly proportions of 2025 fatalities from January to June averaged 5.4%. They ranged from a high of 6.1% in February to a low of 4.8% in March. During 2024, fatal overdoses constituted 5.8% of all overdoses, just slightly lower than 2023 (6.1%) (Sorg et al. 2025). Additional resources, data, and visualizations are available at the Maine Drug Data Hub: <https://mainedrugdata.org/>.



**Figure 1:** County-level naloxone distribution levels per 100 residents (with point of initial township distribution indicated by star) by the Maine Naloxone Distribution Initiative from April through June 2025

## Public Health—Tier 1 Distributors

During the second quarter of 2025 (April–June):

**83,218** doses of naloxone have been distributed  
**274** overdose reversals have been voluntarily reported.

From July 2019 through June 2025 (MNDI project-to-date totals):

**709,588** doses of naloxone have been distributed  
**9,720** overdose reversals have been voluntarily reported.

## Public Safety—Law Enforcement Agencies

During the second quarter of 2025 (April–June):

**684** doses of naloxone have been distributed  
**28** overdose reversals have been voluntarily reported.

From July 2019 through June 2025:

**22,608** doses of naloxone have been distributed  
**1,876** overdose reversals have been voluntarily reported.

**Table 1** Doses of naloxone distributed by Tier 1 distributors and OAG

	2019–2023	2024	Jan–Mar 2025	Apr 2025	May 2025	Jun 2025	Total
BPH (IN)	96692	43628	3612	3176	21200	6956	175264
BPH (RI)	0	4416	48	48	4056	0	8568
BPH (IM)	0	0	0	0	13300	0	13300
PPH (IN)	83639	36706	6260	2220	4288	2758	135871
PPH (IM)	1714	1934	500	344	200	300	4992
MG	76354	34888	8206	1764	3624	11062	135898
MAP (IM)	146,481	16654	5440	1148	1096	1180	171999
MAP (IN)	35738	14698	1450	174	144	0	52204
MAP (RI)	0	2454	4858	968	1558	1654	11492
OAG	18324	3180	420	488	96	100	22608
<b>Total</b>	<b>458942</b>	<b>158558</b>	<b>30794</b>	<b>10330</b>	<b>49562</b>	<b>24010</b>	<b>732196</b>

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal; RI = RiVive®. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH January and July, 2020 and March 2021 and PPH April 2021, Jan 2022 and MG March 2020, October, November, December 2021 and March, April 2022. OBH 2019, 2020, 2021 and 2022. (5) Table 1 includes corrections for MAP reporting that include a decrease in IN doses and an increase in IM doses. 1957 doses of IN naloxone were removed from distribution data from 07/2019 to 07/2023 and 13926 doses of IM naloxone were added to distribution data from 07/2019 to 07/2023. (6) Beginning June of 2024, the MNDI will be purchasing and distributing lower dose (3mg) naloxone (RiVive®).

**Table 1.1** Doses of naloxone distributed by Tier 1 distributors to OPTIONS liaisons (subcategory of total distribution)

	2021–2023	2024	Jan–Mar 2025	Apr 2025	May 2025	Jun 2025	Total
BPH	7012	5326	768	536	5840	0	19482
PPH	4150	2548	728	168	192	456	8242
MG	9292	4720	1416	120	384	624	16556
Total	20454	12594	2912	824	6416	1080	44280

Notes: (1) Unit is doses for all values.

**Table 1.2** Doses of naloxone distributed by Tier 1 distributors through syringe services/access programs (subcategory of total distribution)

	2021–2023	2024	Jan–Mar 2025	Apr 2025	May 2025	Jun 2025	Total
BPH	20034	9764	456	488	18616	3260	52618
PPH	25511	9536	2486	1154	1312	1332	41331
MG	8120	2836	344	134	102	202	11738
MAP	97894	32596	11476	2290	2862	2834	149952
Total	151559	54732	14762	4066	22892	7628	255639

Notes: (1) Unit is doses for all values. (2) A revision has been made to BPH March, June, September of 2021 January, April and May of 2022 as well as PPH April 2021 and February of 2023. (3) Missing data for January 2021 for PPH.

**Table 1.3** Doses of naloxone distributed by Tier 1 distributors to EMS Naloxone Leave Behind Program (subcategory of total distribution)

	2022– 2023	2024	Jan–Mar 2025	Apr 2025	May 2025	Jun 2025	Total
BPH	1628	884	142	206	8	60	2928
PPH	1228	510	70	194	0	56	2058
MG	2022	1308	210	190	32	24	3786
Total	4878	2702	422	590	40	140	8772

Notes: (1) Unit is doses for all values. (2) The EMS Leave Behind Program was launched in January of 2022. TIs are to provide EMS agencies across the state with kits of naloxone to provide to anyone who has refused EMS transport.

**Table 2** Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies through the reporting tool called ODMAP

	2019– 2023	2024	Jan–Mar 2025	Apr 2025	May 2025	Jun 2025	Total
BPH	2382	551	68	54	53	46	3154
PPH	1344	402	51	19	18	15	1849
MG	836	216	32	6	11	9	1110
MAP	3063	362	47	11	6	26	3515
OAG	1703	130	15	9	10	9	1876
OD-ME app	77	14	1	0	0	0	92
Total	9405	1675	214	99	98	105	11596

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only. (5) Law enforcement agencies that receive naloxone from the OAG and report reversals through ODMAP are now being included. ODMAP reversal data has been added from July 2019 to present. (6) A revision has been made to MAP 2022 and PPH February 2023 reversal reports as well as OAG Q1 2023

## Works Cited

Marcella H. Sorg, Daniel Soucier, Prianka Maria Sarkar. (2025). *Maine Monthly Overdose Report*. University of Maine. Orono: Margaret Chase Smith Policy Center.